|
Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...
Purer, Less Costly Interferon for Hepatitis C and B Treatment
The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B....
New Technology May Help Treat Hepatitis
While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmelss...
|
|
|
Bull Acad Natl Med 1996 Jun;180(6):1253-1262
[Epidemiology of infections linked to hepatitis C virus in France].
[Article in French]
Roudot-Thoraval F
Departement de Sante Publique, CHU Henri Mondor, Creteil.
In France, the population of adult carriers of anti-HCV antibodies has been estimated
about 600,000, but only 10 to 15% are aware of the diagnosis. Two major sources
of infection have been identified : transfusion and intravenous drug use, accounting
for 60% of HCV infections. In contrast, sexual or household transmission, mother-to-infant
transmission or occupational exposure account for a small part of the HCV epidemic.
In about 15% of cases, a nosocomial exposure is questioned, probably related to
an insufficient decontamination of medical devices. Finally, no source of infection
can be recognized in about 20% of infected patients. Among them, many have spent
a long stay in high HCV prevalence areas, suggesting local percutaneous exposures.
The diagnosis of chronic hepatitis C is often made late in the course of the disease,
an average of 10 years after exposure. At this time, a cirrhosis is present in
about 20% of the patients. The frequency of cirrhosis depends on the duration
of the HCV infection, and probably also on the source of transmission, independently
of the duration of the disease. Thus, it has been observed that cirrhosis was
more frequent in transfusion recipients than in intravenous drug users. Such a
difference could be related to different HCV genotypes in the different groups
at risk. The genotype 1b has been found predominant in transfusion recipients
whereas genotype 3a was more frequent in drug users. Recently, a slight modification
in the relative frequency of the different genotypes, mainly spreading and increased
frequency of genotype 3a could lead to a modified epidemiology of HCV infection.
The consequences of such modifications need to be evaluated.
PMID: 8991607, UI: 97103848
table Of Contents
|
|
